NewsTitan Biotech Limited Submits Annual Secretarial Compliance Report for Financial Year Ended March 31, 2026Titan Biotech Limited Submits Annual Secretarial Compliance Report for Financial Year Ended March 31, 2026
Titan Biotech Limited filed its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, with BSE Limited on May 4, 2026, pursuant to Regulation 24A of SEBI (LODR) Regulations, 2015. The report, issued by Practicing Company Secretary Mr. Amit Anand (M No: ACS-13409, CP No: 17101) on April 24, 2026, confirmed full compliance across all applicable SEBI regulations with no deviations, violations, or regulatory actions recorded. Key compliance areas including secretarial standards, insider trading norms, related party transactions, and website disclosures were all found to be in order. No material subsidiary was identified during the review period, and no observations from previous reports remained unaddressed.
*this image is generated using AI for illustrative purposes only.
Titan Biotech Limited has submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026, to BSE Limited. The report was filed on May 4, 2026, by Compliance Officer Charanjit Singh, pursuant to Regulation 24A of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The secretarial audit was conducted by Practicing Company Secretary Mr. Amit Anand (M No: ACS-13409, CP No: 17101), with the report dated April 24, 2026, and issued from Delhi.
Scope of Examination
The secretarial audit covered an examination of all documents, records, filings, and submissions made by Titan Biotech to the stock exchanges, as well as the company's website and other relevant documents for the financial year ended March 31, 2026. The review assessed compliance with the following key regulatory frameworks:
- SEBI Act, 1992 and regulations, circulars, and guidelines issued thereunder
- Securities Contracts (Regulation) Act, 1956 (SCRA) and rules made thereunder
- SEBI (LODR) Regulations, 2015
- SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011
- SEBI (Prohibition of Insider Trading) Regulations, 2015
Certain regulations were noted as not applicable during the review period, including SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018; SEBI (Buyback of Securities) Regulations, 2018; SEBI (Share Based Employee Benefits and Sweat Equity) Regulations, 2021; and SEBI (Issue and Listing of Non-Convertible Securities) Regulations, 2021.
Compliance Status: No Deviations Recorded
The Practicing Company Secretary confirmed that Titan Biotech complied with all applicable SEBI regulations and circulars during the review period. No deviations, violations, fines, or regulatory actions were reported. The following table summarises the key compliance parameters reviewed:
| Compliance Parameter: | Status | Remarks |
|---|---|---|
| Secretarial Standards (ICSI) | Yes | None |
| Adoption and updation of applicable policies | Yes | None |
| Maintenance and disclosures on website | Yes | None |
| Disqualification of Directors (Section 164, Companies Act, 2013) | Yes | Based on confirmation received from Directors |
| Identification of material subsidiaries | NA | No material subsidiary identified during review period |
| Disclosure requirements for subsidiaries | Yes | Policy for determining material subsidiary is in place |
| Preservation of documents | Yes | None |
| Performance evaluation of board and committees | Yes | None |
| Related party transactions – prior audit committee approval | Yes | None |
| Disclosure of events or information (Regulation 30) | Yes | None |
| Prohibition of Insider Trading (Regulation 3(5) & 3(6)) | Yes | Company has proper Structural Digital Database software |
| Actions taken by SEBI or Stock Exchanges | Yes | None |
| Resignation of statutory auditors | NA | No resignation of statutory auditors during the review period |
| Additional non-compliances | Yes | No additional non-compliance observed |
Actions on Previous Report Observations
The report also confirmed that there were no pending observations from previous secretarial compliance reports requiring remedial action. All entries under this section were marked as NA, indicating a clean compliance record carried forward from prior periods.
Assumptions and Limitations
The Practicing Company Secretary noted the following key limitations of the report:
- Compliance with applicable laws and the authenticity of documents furnished are the responsibility of the management of the listed entity.
- The report is based on examination of relevant documents and information and is neither an audit nor an expression of opinion.
- The correctness and appropriateness of financial records and books of account were not verified.
- The report is solely for the purpose of compliance under Regulation 24A(2) of the SEBI (LODR) Regulations, 2015, and does not constitute an assurance regarding the future viability of the entity or the efficacy of management conduct.
The report was signed by Amit Anand, Practicing Company Secretary, with UDIN: A013409H000196240 and Peer Review No.: 1970/2022, at Delhi on April 24, 2026.
Historical Stock Returns for Titan Biotech
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +0.20% | +1.20% | +8.59% | +131.01% | +439.28% | +673.30% |
How might Titan Biotech's consistent clean compliance record influence its ability to raise capital or attract institutional investors in the near future?
Given that regulations like SEBI's Issue of Capital and Disclosure Requirements were marked as not applicable, could Titan Biotech be planning any equity issuance or fundraising activities in FY2027?
With no material subsidiaries identified during the review period, is Titan Biotech considering any acquisitions or subsidiary formations that could change its corporate structure going forward?
19
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
